| Abstrakt: |
This document is a correction notice for an article titled "Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid" published in the Journal of Neurology. The correction addresses errors in the original article, including misinformed information about CSF MOG antibody testing and a small error in reporting CSF MOG values. The corrections do not change the meaning, data, or interpretation of the results. The given text appears to be a table showing different neurological conditions and their corresponding number of cases. The conditions listed include primary psychiatric, movement disorder, peripheral nerve, neurosarcoidosis, CNS vasculitis, brain cancer/tumor, vision other, inflammatory brain disorder, idiopathic intracranial hypertension, seizure disorder, systemic lupus Erythematosus, PRES, normal, and other/unknown. The table also includes information about CSF MOG staining and immunotherapy timing for certain patients. The article discusses the use of various immunotherapies for the treatment of MOG antibody-associated disorders (MOGAD). It highlights the challenges in interpreting weakly positive titers as a reliable diagnostic tool for MOGAD. The study found that in their current research, 4 out of 5 cerebrospinal fluid (CSF) MOG staining results were weak, suggesting the need for further investigation into the diagnostic criteria for MOGAD. The authors provide valuable insights into the limitations and [Extracted from the article] |
Full text from SpringerLink